9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023
The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professio...
Saved in:
| Published in | Diabetes care Vol. 46; no. Supplement_1; pp. S140 - S157 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
American Diabetes Association
01.01.2023
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC. |
|---|---|
| AbstractList | The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations and a full list of Professional Practice Committee members, please refer to
Introduction and Methodology
. Readers who wish to comment on the Standards of Care are invited to do so at
professional.diabetes.org/SOC
. The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC. The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC. |
| Author | Lyons, Sarah K. Isaacs, Diana Perry, Mary Lou Hilliard, Marisa E. Seley, Jane Jeffrie Gabbay, Robert A. Brown, Florence M. Aleppo, Grazia Aroda, Vanita R. Pratley, Richard E. Khunti, Kamlesh Stanton, Robert C. Kahan, Scott Johnson, Eric L. Bannuru, Raveendhara R. Bruemmer, Dennis Prahalad, Priya ElSayed, Nuha A. Leon, Jose Collins, Billy S. |
| Author_xml | – sequence: 1 givenname: Nuha A. surname: ElSayed fullname: ElSayed, Nuha A. – sequence: 2 givenname: Grazia surname: Aleppo fullname: Aleppo, Grazia – sequence: 3 givenname: Vanita R. surname: Aroda fullname: Aroda, Vanita R. – sequence: 4 givenname: Raveendhara R. surname: Bannuru fullname: Bannuru, Raveendhara R. – sequence: 5 givenname: Florence M. surname: Brown fullname: Brown, Florence M. – sequence: 6 givenname: Dennis surname: Bruemmer fullname: Bruemmer, Dennis – sequence: 7 givenname: Billy S. surname: Collins fullname: Collins, Billy S. – sequence: 8 givenname: Marisa E. surname: Hilliard fullname: Hilliard, Marisa E. – sequence: 9 givenname: Diana surname: Isaacs fullname: Isaacs, Diana – sequence: 10 givenname: Eric L. surname: Johnson fullname: Johnson, Eric L. – sequence: 11 givenname: Scott surname: Kahan fullname: Kahan, Scott – sequence: 12 givenname: Kamlesh surname: Khunti fullname: Khunti, Kamlesh – sequence: 13 givenname: Jose surname: Leon fullname: Leon, Jose – sequence: 14 givenname: Sarah K. surname: Lyons fullname: Lyons, Sarah K. – sequence: 15 givenname: Mary Lou surname: Perry fullname: Perry, Mary Lou – sequence: 16 givenname: Priya surname: Prahalad fullname: Prahalad, Priya – sequence: 17 givenname: Richard E. surname: Pratley fullname: Pratley, Richard E. – sequence: 18 givenname: Jane Jeffrie surname: Seley fullname: Seley, Jane Jeffrie – sequence: 19 givenname: Robert C. surname: Stanton fullname: Stanton, Robert C. – sequence: 20 givenname: Robert A. surname: Gabbay fullname: Gabbay, Robert A. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36507650$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkc9qFTEUxkOp2Nvqoi8gWepi2vyZ_OtCKNdahYJCKy7DmcyZ3pSZyTWZK3TnQ_QJ-ySdS2tRcXFy4OSX7zvk2ye7YxqRkEPOjoSU5rgNQlaXjLkdsuBOqkqp2u6SBeO1q5RzYo_sl3LDGKtra1-SPakVM3MtyHd3RL-uIA8QUp-uY6Cn63VOEFZY6JToeX8bcJjHVxlhGnCcTujlBGMLuS00dXQJGWkc6YcIDU5Y7n_dCSbkK_Kig77g66d-QL59PLtafqouvpx_Xp5eVEEq7eYzNMa2WgTQUhtuhNChC8pyIdFytA2XrekkamtqaJ2ujQqhaV3jGDQM5AF5_6i73jQDtmFeMEPv1zkOkG99guj_vhnjyl-nn95ZzmqjZ4G3TwI5_dhgmfwQS8C-hxHTpnhhlNTaMlvP6Js_vZ5Nfv_mDLx7BEJOpWTsnhHO_DYpv03Kb5Oa2eN_2BAnmGLarhn7_7x4AEOulfE |
| CitedBy_id | crossref_primary_10_1007_s13659_023_00424_w crossref_primary_10_1002_agm2_12294 crossref_primary_10_1080_14789450_2023_2295866 crossref_primary_10_1177_10600280241227973 crossref_primary_10_18632_aging_205709 crossref_primary_10_7759_cureus_72184 crossref_primary_10_15829_1560_4071_2024_6074 crossref_primary_10_1016_j_pcd_2024_06_013 crossref_primary_10_2196_60758 crossref_primary_10_3390_ph17040478 crossref_primary_10_17925_EE_2023_19_1_4 crossref_primary_10_1016_j_amjcard_2024_02_039 crossref_primary_10_1016_j_jdiacomp_2023_108625 crossref_primary_10_1097_01_JAA_0001007388_97793_41 crossref_primary_10_1007_s00210_024_03088_6 crossref_primary_10_1007_s13340_023_00651_z crossref_primary_10_1136_bmjdrc_2022_003302 crossref_primary_10_1371_journal_pone_0292014 crossref_primary_10_1016_j_semerg_2024_102220 crossref_primary_10_1016_S2213_8587_24_00154_2 crossref_primary_10_1055_s_0043_1761205 crossref_primary_10_4239_wjd_v16_i1_95209 crossref_primary_10_1016_j_japh_2024_102124 crossref_primary_10_1007_s13300_023_01378_5 crossref_primary_10_15406_jdmdc_2024_11_00281 crossref_primary_10_3389_fphar_2023_1301931 crossref_primary_10_3390_molecules28020751 crossref_primary_10_1002_cpdd_1497 crossref_primary_10_1093_jbmrpl_ziae003 crossref_primary_10_22159_ajpcr_2024_v17i6_50741 crossref_primary_10_3390_jcm13206225 crossref_primary_10_1016_j_pcd_2024_06_003 crossref_primary_10_1097_MD_0000000000034696 crossref_primary_10_1007_s13300_024_01615_5 crossref_primary_10_18553_jmcp_2023_29_6_699 crossref_primary_10_1007_s40618_024_02306_5 crossref_primary_10_4236_ijcm_2023_1412045 crossref_primary_10_1007_s40265_023_01992_4 crossref_primary_10_1161_HYPERTENSIONAHA_123_20598 crossref_primary_10_1177_10815589241270427 crossref_primary_10_1007_s11695_024_07178_5 crossref_primary_10_1177_08971900241256775 crossref_primary_10_1136_bmjdrc_2022_003206 crossref_primary_10_1007_s11606_023_08589_3 crossref_primary_10_1016_j_diabres_2024_111604 crossref_primary_10_2147_PPA_S436540 crossref_primary_10_3897_pharmacia_71_e132148 crossref_primary_10_1001_jamanetworkopen_2024_23385 crossref_primary_10_1016_j_diabres_2024_111722 crossref_primary_10_2147_PPA_S401465 crossref_primary_10_3390_medicina60030357 crossref_primary_10_4239_wjd_v15_i6_1086 crossref_primary_10_1016_j_pcd_2023_12_004 crossref_primary_10_1016_S1957_2557_23_00297_3 crossref_primary_10_1016_j_jclinane_2024_111693 crossref_primary_10_1097_FJC_0000000000001556 crossref_primary_10_1111_apha_14226 crossref_primary_10_1055_s_0043_1771027 crossref_primary_10_1016_j_diabet_2025_101605 crossref_primary_10_1111_dom_16161 crossref_primary_10_1111_dom_15192 crossref_primary_10_1016_j_ajogmf_2023_101129 crossref_primary_10_1007_s13410_023_01222_3 crossref_primary_10_1016_j_diabres_2023_110669 crossref_primary_10_1007_s13300_023_01467_5 crossref_primary_10_7759_cureus_46091 crossref_primary_10_1016_S2352_4642_24_00019_1 crossref_primary_10_4103_ijdt_ijdt_33_23 crossref_primary_10_1016_j_cegh_2024_101805 crossref_primary_10_36290_vnl_2024_006 crossref_primary_10_1089_met_2023_0227 crossref_primary_10_17925_EE_2023_19_1_38 crossref_primary_10_3390_pharmacy11020058 crossref_primary_10_20344_amp_20858 crossref_primary_10_1007_s40273_023_01282_7 crossref_primary_10_1080_14740338_2023_2193393 crossref_primary_10_1007_s40619_023_01410_7 crossref_primary_10_2337_ds23_0052 crossref_primary_10_3389_fphar_2025_1509561 crossref_primary_10_4330_wjc_v16_i8_448 crossref_primary_10_1097_01_NPR_0000000000000100 crossref_primary_10_1016_S2213_8587_23_00093_1 crossref_primary_10_1186_s13098_024_01334_8 crossref_primary_10_1016_j_bja_2024_01_001 crossref_primary_10_1002_cpdd_1450 crossref_primary_10_3390_biomedicines11123115 crossref_primary_10_3390_jcm13185403 crossref_primary_10_1001_jamainternmed_2023_8029 crossref_primary_10_4239_wjd_v15_i10_2135 crossref_primary_10_1210_jcemcr_luad167 crossref_primary_10_1186_s12902_024_01577_6 crossref_primary_10_3390_cells12232691 crossref_primary_10_1016_j_molmet_2024_101956 crossref_primary_10_1186_s13098_023_01118_6 crossref_primary_10_7759_cureus_74345 crossref_primary_10_1001_jamanetworkopen_2024_0946 crossref_primary_10_1016_j_diabres_2023_110884 crossref_primary_10_1053_j_ajkd_2023_04_009 crossref_primary_10_1186_s12916_024_03518_5 crossref_primary_10_1016_j_jdiacomp_2023_108566 crossref_primary_10_1053_j_jvca_2023_08_149 crossref_primary_10_1177_20101058231204703 crossref_primary_10_1007_s40261_023_01317_z crossref_primary_10_18553_jmcp_2023_23277 crossref_primary_10_1007_s00592_024_02285_2 crossref_primary_10_18553_jmcp_2024_30_12_1375 crossref_primary_10_1155_2024_5553327 crossref_primary_10_1111_dom_16077 crossref_primary_10_1016_j_diabet_2024_101578 crossref_primary_10_1016_j_diabres_2023_110777 crossref_primary_10_3390_jcm12237260 crossref_primary_10_1007_s12170_023_00724_3 crossref_primary_10_1016_j_diabres_2023_110779 crossref_primary_10_2337_ds22_0064 crossref_primary_10_1186_s12933_023_01798_4 crossref_primary_10_1016_j_arteri_2024_02_001 crossref_primary_10_2337_dc23_1129 crossref_primary_10_3390_diagnostics14070733 crossref_primary_10_1016_j_jamda_2023_06_033 crossref_primary_10_1016_j_jdiacomp_2023_108436 crossref_primary_10_1016_j_jacc_2024_01_040 crossref_primary_10_1080_03007995_2024_2322072 crossref_primary_10_2337_ds22_0095 crossref_primary_10_22141_2224_0721_19_5_2023_1297 crossref_primary_10_3389_fmars_2024_1438955 crossref_primary_10_3390_plants12102014 crossref_primary_10_1016_j_pcd_2024_12_002 crossref_primary_10_3390_v15071514 crossref_primary_10_3390_jcm13216532 crossref_primary_10_1186_s13098_023_01251_2 crossref_primary_10_4103_jod_jod_19_24 crossref_primary_10_4236_jdm_2023_134022 crossref_primary_10_1111_dom_15811 crossref_primary_10_1080_14740338_2024_2446431 crossref_primary_10_1590_2175_8239_jbn_2023_0187pt crossref_primary_10_1126_sciadv_adj7067 crossref_primary_10_1007_s00223_024_01240_1 crossref_primary_10_1080_17446651_2023_2210673 crossref_primary_10_1056_NEJMoa2403953 crossref_primary_10_1007_s13300_024_01611_9 crossref_primary_10_1016_j_ejim_2023_07_005 crossref_primary_10_1007_s11901_023_00629_0 crossref_primary_10_1111_dme_15298 crossref_primary_10_1055_a_2318_3452 crossref_primary_10_1089_thy_2023_0530 crossref_primary_10_1186_s13098_023_01240_5 crossref_primary_10_1177_87551225241266773 crossref_primary_10_4070_kcj_2024_0214 crossref_primary_10_3390_biomedicines11113051 crossref_primary_10_1016_j_ekir_2023_01_033 crossref_primary_10_1080_17446651_2025_2459720 crossref_primary_10_3390_jcm12186052 crossref_primary_10_1007_s13300_025_01700_3 crossref_primary_10_1080_08998280_2024_2379195 crossref_primary_10_3389_fphar_2023_1181312 crossref_primary_10_1177_2633559X231202497 crossref_primary_10_1007_s40273_023_01268_5 crossref_primary_10_1007_s11357_023_01009_8 crossref_primary_10_5195_ijms_2024_1932 crossref_primary_10_1007_s13300_023_01471_9 crossref_primary_10_1007_s12011_024_04397_w crossref_primary_10_1053_j_jvca_2023_10_011 crossref_primary_10_3389_fcell_2023_1167097 crossref_primary_10_1007_s11606_023_08067_w crossref_primary_10_3390_diagnostics13172817 crossref_primary_10_1016_j_diabres_2024_111685 crossref_primary_10_2337_dc23_1332 crossref_primary_10_1111_dom_15918 crossref_primary_10_4103_ijem_ijem_377_23 crossref_primary_10_1016_j_jdiacomp_2023_108476 crossref_primary_10_2337_dci23_0023 crossref_primary_10_1007_s13340_024_00721_w crossref_primary_10_4239_wjd_v16_i2_98552 crossref_primary_10_36469_jheor_2024_91396 crossref_primary_10_1210_clinem_dgae038 crossref_primary_10_3390_jcm12123925 crossref_primary_10_1111_jdi_14285 crossref_primary_10_1136_bmjdrc_2023_003696 crossref_primary_10_1016_j_jdiacomp_2024_108777 crossref_primary_10_1097_MNH_0000000000000976 crossref_primary_10_1007_s13300_023_01509_y crossref_primary_10_7759_cureus_61766 crossref_primary_10_1159_000531432 crossref_primary_10_1016_j_clinthera_2024_06_023 crossref_primary_10_1016_j_dsx_2023_102747 crossref_primary_10_1111_dom_15609 crossref_primary_10_1016_j_clinthera_2023_02_003 crossref_primary_10_2337_dc23_1782 crossref_primary_10_2147_DMSO_S464671 crossref_primary_10_3390_cimb46120872 crossref_primary_10_1016_j_eprac_2024_12_005 crossref_primary_10_1210_endrev_bnad037 crossref_primary_10_7759_cureus_80050 crossref_primary_10_4103_jod_jod_96_23 crossref_primary_10_1007_s00592_024_02415_w crossref_primary_10_1093_ndt_gfad112 crossref_primary_10_1016_S0140_6736_23_01127_3 crossref_primary_10_1136_bmjmed_2022_000372 crossref_primary_10_1007_s12020_024_03868_3 crossref_primary_10_1186_s12882_024_03504_2 crossref_primary_10_2337_dc23_1791 crossref_primary_10_3390_life13061265 crossref_primary_10_1016_j_eprac_2024_06_002 crossref_primary_10_1136_bmjopen_2023_075840 crossref_primary_10_1093_gerona_glae108 crossref_primary_10_4103_jfmpc_jfmpc_829_23 crossref_primary_10_1016_j_eprac_2024_06_007 crossref_primary_10_1016_j_clinthera_2023_10_014 crossref_primary_10_3390_jcdd10080322 crossref_primary_10_1089_dia_2024_0041 crossref_primary_10_1186_s40001_024_02241_4 crossref_primary_10_1002_phar_2928 crossref_primary_10_1210_endocr_bqad166 crossref_primary_10_1001_jama_2023_13872 crossref_primary_10_3389_fmed_2024_1384454 crossref_primary_10_1016_S0140_6736_23_01302_8 crossref_primary_10_1111_acem_14922 crossref_primary_10_1111_dom_15705 crossref_primary_10_3390_pharmaceutics16091192 crossref_primary_10_58931_cpct_2023_1322 crossref_primary_10_1016_j_diabres_2024_111770 crossref_primary_10_1002_jgf2_664 crossref_primary_10_3390_pharmaceutics15082111 crossref_primary_10_1007_s10534_025_00673_x crossref_primary_10_3390_ph17091249 crossref_primary_10_1210_endrev_bnae026 crossref_primary_10_1007_s13300_024_01625_3 crossref_primary_10_1016_j_repc_2024_04_011 crossref_primary_10_3389_fendo_2024_1286827 crossref_primary_10_1002_oby_23925 crossref_primary_10_1007_s13300_023_01497_z crossref_primary_10_3390_ijms25073832 crossref_primary_10_2147_DMSO_S392684 crossref_primary_10_1007_s13300_023_01473_7 crossref_primary_10_1093_ndt_gfae229 crossref_primary_10_3390_nu15214663 crossref_primary_10_1093_ndt_gfae227 crossref_primary_10_1038_s41746_024_01028_5 crossref_primary_10_1080_03007995_2024_2401096 crossref_primary_10_1186_s40360_023_00716_4 crossref_primary_10_2337_dc23_1648 crossref_primary_10_1016_j_ahj_2025_01_003 crossref_primary_10_1001_jama_2023_11313 crossref_primary_10_1038_s41584_024_01092_x crossref_primary_10_1097_01_NURSE_0000927496_48856_2f crossref_primary_10_1111_jdi_14363 crossref_primary_10_1002_jac5_2033 crossref_primary_10_1016_S0140_6736_23_02179_7 crossref_primary_10_1111_1753_0407_13428 crossref_primary_10_1055_s_0045_1805026 crossref_primary_10_1111_dom_15529 crossref_primary_10_2147_DMSO_S390752 crossref_primary_10_1111_dom_15526 crossref_primary_10_1210_clinem_dgad216 crossref_primary_10_1080_13543784_2023_2263354 crossref_primary_10_1111_dom_15409 crossref_primary_10_1007_s13300_024_01531_8 crossref_primary_10_1177_10600280231178886 crossref_primary_10_1002_jppr_1913 crossref_primary_10_1016_j_eclinm_2024_102482 crossref_primary_10_1111_dom_15645 crossref_primary_10_1377_hlthaff_2024_00118 crossref_primary_10_3389_fendo_2024_1387993 crossref_primary_10_1136_bmj_2022_072686 crossref_primary_10_1038_s41598_024_52603_5 crossref_primary_10_4239_wjd_v15_i5_828 crossref_primary_10_1093_jncics_pkae095 crossref_primary_10_1016_j_clinthera_2024_03_001 crossref_primary_10_3390_healthcare11040541 crossref_primary_10_1080_19336950_2023_2281743 crossref_primary_10_4103_tjem_tjem_110_23 crossref_primary_10_1016_j_artere_2024_06_001 crossref_primary_10_1007_s13300_024_01589_4 crossref_primary_10_1080_14656566_2023_2276180 crossref_primary_10_1159_000539120 crossref_primary_10_2147_DMSO_S443115 crossref_primary_10_1155_2023_6955723 crossref_primary_10_19163_2307_9266_2023_11_4_324_346 crossref_primary_10_2337_dbi23_0022 crossref_primary_10_1007_s11428_024_01246_1 crossref_primary_10_1007_s13300_024_01556_z crossref_primary_10_18772_26180197_2024_v6n1a2 crossref_primary_10_1002_jac5_2050 crossref_primary_10_2337_cd23_0063 crossref_primary_10_3390_jcm13051367 crossref_primary_10_3389_fendo_2024_1405031 crossref_primary_10_21518_ms2024_127 crossref_primary_10_1111_1475_6773_14152 crossref_primary_10_1007_s11255_023_03798_5 crossref_primary_10_1097_NHH_0000000000001223 crossref_primary_10_25259_IJCDW_73_2023 crossref_primary_10_1111_dme_15339 crossref_primary_10_2147_RMHP_S455897 crossref_primary_10_1007_s11606_024_08907_3 crossref_primary_10_1161_CIR_0000000000001186 crossref_primary_10_1210_clinem_dgad113 crossref_primary_10_34067_KID_0000000597 crossref_primary_10_1111_jdi_14212 crossref_primary_10_1007_s13340_023_00637_x crossref_primary_10_1007_s11892_024_01540_8 crossref_primary_10_1097_NHH_0000000000001216 crossref_primary_10_2337_cd22_0118 crossref_primary_10_1038_s41598_023_41036_1 crossref_primary_10_3390_biom14010137 crossref_primary_10_1152_ajpheart_00141_2023 crossref_primary_10_4103_jod_jod_115_23 crossref_primary_10_1007_s11030_023_10680_0 crossref_primary_10_1590_2175_8239_jbn_2023_0187en crossref_primary_10_3390_nu16010063 crossref_primary_10_2337_cd22_0110 crossref_primary_10_1186_s41100_023_00492_1 crossref_primary_10_1097_NHH_0000000000001232 crossref_primary_10_1007_s00125_024_06126_3 crossref_primary_10_3390_jcm12206462 crossref_primary_10_2337_cd23_0047 crossref_primary_10_1016_j_jsps_2023_04_022 crossref_primary_10_36011_cpp_2023_5_e8 crossref_primary_10_3389_fendo_2023_1222409 crossref_primary_10_1001_jamainternmed_2023_8526 crossref_primary_10_1038_s41591_023_02552_9 crossref_primary_10_1007_s13300_024_01557_y crossref_primary_10_1016_j_mayocp_2024_08_015 crossref_primary_10_2337_cd23_0042 crossref_primary_10_1515_jbcpp_2022_0305 crossref_primary_10_1016_j_medcle_2024_02_015 crossref_primary_10_1016_j_pcd_2024_03_001 crossref_primary_10_2337_cd23_0044 crossref_primary_10_1080_00325481_2024_2331417 crossref_primary_10_1016_j_clinre_2023_102279 crossref_primary_10_1016_j_metabol_2023_155692 crossref_primary_10_14341_DM13193 crossref_primary_10_33590_emj_10306493 crossref_primary_10_1161_JAHA_123_033860 crossref_primary_10_1007_s13300_025_01701_2 crossref_primary_10_1111_dom_15565 crossref_primary_10_1016_S2666_7568_23_00177_0 crossref_primary_10_3390_biomedicines11030670 crossref_primary_10_1111_dom_15327 crossref_primary_10_3390_jcm13082196 crossref_primary_10_1136_bmj_2023_078483 crossref_primary_10_1111_dom_15682 crossref_primary_10_1016_j_eprac_2023_12_007 crossref_primary_10_7759_cureus_36438 crossref_primary_10_2967_jnmt_123_266800 crossref_primary_10_1016_j_clnesp_2025_02_016 crossref_primary_10_1093_ehjcvp_pvae006 crossref_primary_10_1007_s40618_023_02259_1 crossref_primary_10_3389_fendo_2023_1268308 crossref_primary_10_3390_biomedicines11030662 crossref_primary_10_1016_j_japh_2023_06_003 crossref_primary_10_1007_s00592_024_02443_6 crossref_primary_10_3389_fendo_2025_1528801 crossref_primary_10_1080_17520363_2024_2432309 crossref_primary_10_1111_jebm_12620 crossref_primary_10_1007_s13300_024_01610_w crossref_primary_10_1093_ageing_afae175 crossref_primary_10_1111_dom_15451 crossref_primary_10_1007_s11102_024_01397_w crossref_primary_10_1111_1753_0407_13526 crossref_primary_10_5144_0256_4947_2024_296 crossref_primary_10_1038_s41598_024_52101_8 crossref_primary_10_1007_s11883_023_01181_4 crossref_primary_10_3390_endocrines4030035 crossref_primary_10_1016_j_envpol_2023_121883 crossref_primary_10_3389_fendo_2024_1455465 crossref_primary_10_1007_s00125_024_06158_9 crossref_primary_10_3390_ijms24043385 crossref_primary_10_1016_j_heliyon_2024_e30787 crossref_primary_10_1016_j_deman_2023_100151 crossref_primary_10_1111_jdi_14415 crossref_primary_10_1039_D4LC00365A crossref_primary_10_1111_dom_15425 crossref_primary_10_1016_j_eclinm_2023_102181 crossref_primary_10_1055_a_2463_9784 crossref_primary_10_1111_dom_15789 crossref_primary_10_4103_bjem_bjem_26_23 crossref_primary_10_2337_cd23_0093 crossref_primary_10_4103_ijem_ijem_189_23 crossref_primary_10_1053_j_ajkd_2023_10_001 crossref_primary_10_3389_fendo_2023_1182037 crossref_primary_10_1007_s13300_023_01416_2 crossref_primary_10_1093_inthealth_ihad080 crossref_primary_10_21518_ms2023_439 crossref_primary_10_1186_s13098_023_01231_6 crossref_primary_10_3389_fendo_2023_1256548 crossref_primary_10_1080_03007995_2024_2312160 crossref_primary_10_1007_s13300_023_01470_w crossref_primary_10_3389_fphar_2023_1226778 crossref_primary_10_1053_j_semvascsurg_2024_04_006 crossref_primary_10_1111_ctr_15257 crossref_primary_10_1111_dom_15312 crossref_primary_10_1016_j_ahj_2023_09_007 crossref_primary_10_1016_j_schres_2024_06_030 crossref_primary_10_1097_MEG_0000000000002754 crossref_primary_10_1007_s00125_024_06257_7 crossref_primary_10_1136_bmj_2023_078015 crossref_primary_10_2337_dc24_0011 crossref_primary_10_1016_j_jaccao_2023_07_004 crossref_primary_10_22141_2224_0721_19_3_2023_1274 crossref_primary_10_1007_s40200_024_01406_6 crossref_primary_10_1016_j_arteri_2024_08_004 crossref_primary_10_1016_j_rccl_2023_04_006 crossref_primary_10_1016_S0140_6736_23_00520_2 crossref_primary_10_1186_s12913_024_11520_z crossref_primary_10_1016_j_diabres_2023_110742 crossref_primary_10_4103_ijdt_ijdt_23_23 crossref_primary_10_1111_dom_15125 crossref_primary_10_1016_j_nurpra_2024_105130 crossref_primary_10_1016_j_imu_2023_101267 crossref_primary_10_2337_dc23_0925 crossref_primary_10_3390_nu15194110 crossref_primary_10_3390_jcm12185989 crossref_primary_10_1007_s13300_023_01458_6 crossref_primary_10_1111_dom_15240 crossref_primary_10_3389_fpubh_2023_1066633 crossref_primary_10_7759_cureus_51093 crossref_primary_10_1093_eurheartjsupp_suae086 crossref_primary_10_1001_jamacardio_2023_1266 crossref_primary_10_1136_bmjopen_2024_086424 crossref_primary_10_1007_s12020_024_04033_6 crossref_primary_10_1016_S0140_6736_23_01233_3 crossref_primary_10_4239_wjd_v15_i6_1142 crossref_primary_10_1186_s12875_024_02390_9 crossref_primary_10_1111_dom_15377 crossref_primary_10_1111_dom_15499 crossref_primary_10_2337_cd23_0101 crossref_primary_10_3389_fpsyt_2024_1473832 crossref_primary_10_1007_s00125_023_05971_y crossref_primary_10_3389_fmed_2023_1158454 crossref_primary_10_3389_fendo_2024_1395651 crossref_primary_10_1007_s00432_025_06154_5 crossref_primary_10_1097_AOG_0000000000005672 crossref_primary_10_1002_ncp_11073 crossref_primary_10_3389_fendo_2024_1372992 crossref_primary_10_1016_j_diabet_2024_101522 crossref_primary_10_31083_j_rcm2507270 crossref_primary_10_1186_s12951_025_03190_8 crossref_primary_10_1016_j_nutres_2025_03_002 crossref_primary_10_3390_jcm13195786 crossref_primary_10_1007_s40200_024_01472_w crossref_primary_10_1056_NEJMoa2303208 crossref_primary_10_1080_14656566_2023_2244420 crossref_primary_10_21518_ms2024_437 crossref_primary_10_1111_dom_15222 crossref_primary_10_1111_dom_15106 crossref_primary_10_1007_s00125_023_06015_1 crossref_primary_10_4103_cdrp_cdrp_8_23 crossref_primary_10_1007_s13300_023_01479_1 crossref_primary_10_1016_j_medj_2022_12_008 crossref_primary_10_2196_56067 crossref_primary_10_21876_hsjhci_v14_2024_e1500 crossref_primary_10_1007_s13300_024_01540_7 crossref_primary_10_1016_j_metop_2024_100285 crossref_primary_10_1007_s11606_023_08402_1 crossref_primary_10_1111_dom_15597 crossref_primary_10_1016_j_lana_2023_100641 crossref_primary_10_1080_14740338_2023_2288897 crossref_primary_10_1111_dom_15596 crossref_primary_10_1155_2024_8915591 crossref_primary_10_1177_00185787231185868 crossref_primary_10_1016_j_jacc_2023_03_393 crossref_primary_10_1002_kjm2_12762 crossref_primary_10_1208_s12248_024_00962_2 crossref_primary_10_1016_j_bone_2024_117238 crossref_primary_10_1111_dom_15351 crossref_primary_10_1177_17407745231193137 crossref_primary_10_1016_j_diabet_2023_101488 crossref_primary_10_1016_j_diabet_2024_101545 crossref_primary_10_1177_10600280231199852 crossref_primary_10_3390_nu15143092 crossref_primary_10_2337_dc24_0859 crossref_primary_10_3897_pharmacia_71_e126255 crossref_primary_10_4103_jod_jod_35_24 crossref_primary_10_2147_PPA_S486553 crossref_primary_10_3389_fphar_2024_1443175 crossref_primary_10_2147_DMSO_S472968 crossref_primary_10_4254_wjh_v16_i8_1120 crossref_primary_10_1111_dom_16014 crossref_primary_10_1038_s41433_024_03112_2 crossref_primary_10_1080_17446651_2023_2290488 crossref_primary_10_3389_fendo_2023_1216160 crossref_primary_10_1111_dom_15163 crossref_primary_10_1080_16089677_2024_2416846 crossref_primary_10_1001_jamanetworkopen_2023_35797 crossref_primary_10_1002_jbm4_10817 crossref_primary_10_2147_DMSO_S415949 crossref_primary_10_1016_j_diabres_2023_110836 crossref_primary_10_1007_s40261_024_01354_2 crossref_primary_10_1001_jamaoto_2024_4852 crossref_primary_10_1007_s12325_023_02761_1 crossref_primary_10_7759_cureus_44644 crossref_primary_10_1038_s44161_024_00453_9 crossref_primary_10_1371_journal_pmed_1004309 crossref_primary_10_2337_cd23_0023 crossref_primary_10_1111_dom_15292 crossref_primary_10_1089_dia_2023_0390 crossref_primary_10_1007_s13346_024_01531_y crossref_primary_10_1007_s15006_023_2996_7 crossref_primary_10_1111_dom_16144 crossref_primary_10_1007_s12020_024_03970_6 crossref_primary_10_2169_internalmedicine_2707_23 crossref_primary_10_1111_dom_16021 crossref_primary_10_1016_j_yfrne_2024_101131 crossref_primary_10_1007_s13340_023_00664_8 crossref_primary_10_1089_met_2024_0127 crossref_primary_10_1186_s12933_023_01827_2 crossref_primary_10_1093_ageing_afae237 crossref_primary_10_3390_cancers16071287 crossref_primary_10_2337_dc23_2051 crossref_primary_10_2337_dc23_2056 crossref_primary_10_17476_jmbs_2023_12_2_26 crossref_primary_10_2337_dc23_2176 crossref_primary_10_4239_wjd_v15_i6_1178 crossref_primary_10_1016_S0140_6736_23_02227_4 crossref_primary_10_1155_2023_9516059 crossref_primary_10_1007_s13410_024_01368_8 crossref_primary_10_1016_j_compbiolchem_2024_108074 crossref_primary_10_1016_j_japh_2024_01_003 crossref_primary_10_1186_s12933_023_01991_5 crossref_primary_10_2337_cd23_0016 crossref_primary_10_1177_10600280231189508 crossref_primary_10_1111_cob_12609 crossref_primary_10_1186_s13098_023_01212_9 crossref_primary_10_1038_s41598_024_59390_z crossref_primary_10_1016_j_ijcard_2024_132109 crossref_primary_10_1007_s13300_024_01542_5 crossref_primary_10_4103_bjem_bjem_1_24 crossref_primary_10_1111_dom_15278 crossref_primary_10_1111_dom_16005 crossref_primary_10_1007_s40615_023_01619_0 crossref_primary_10_2196_53835 crossref_primary_10_1007_s13410_024_01321_9 crossref_primary_10_1111_dom_15035 crossref_primary_10_1111_dom_16008 crossref_primary_10_1186_s12876_023_03085_8 crossref_primary_10_3389_fendo_2024_1395630 crossref_primary_10_1053_j_ajkd_2024_08_003 crossref_primary_10_1111_dom_15274 crossref_primary_10_1111_dom_15393 |
| Cites_doi | 10.2337/dc14-1140 10.1001/jama.289.17.2254 10.1016/j.mayocp.2016.06.010 10.1016/j.ecl.2012.03.001 10.2337/dc05-1365 10.2337/dc16-0690 10.1001/jama.2018.7993 10.1016/S0140-6736(18)31947-0 10.1001/jama.2016.11708 10.1089/dia.2016.0421 10.1007/s00125-005-0132-0 10.2337/dc09-2011 10.2337/dc15-0100 10.2337/db06-0653 10.2337/dc15-2399 10.2337/dcS15-3007 10.1111/dom.12233 10.1056/NEJMoa1303576 10.2337/diacare.26.11.3080 10.2337/dc16-1957 10.2337/dc14-3053 10.2337/dc15-0075 10.1111/j.1742-1241.2012.02911.x 10.1111/j.1463-1326.2009.01060.x 10.1111/dom.12805 10.2337/dc18-2316 10.1056/NEJMoa052187 10.1001/jamainternmed.2014.2894 10.1016/S0140-6736(14)61335-0 10.1111/dom.12532 10.7326/0003-4819-154-9-201105030-00336 10.1056/NEJMoa2108269 10.7326/M20-0864 10.2337/dc16-1495 10.1210/jc.2015-3754 10.1111/dom.12618 10.1056/NEJMoa1615692 10.1001/jama.287.19.2563 10.2337/dc14-0876 10.1136/bmj.g5459 10.2337/dc15-0249 10.1111/j.1464-5491.2004.01319.x 10.1111/1753-0407.12060 10.1089/dia.2018.0200 10.1016/S0140-6736(19)31271-1 10.1016/S2213-8587(17)30194-8 10.2337/dc19-2550 10.1001/jama.2017.7115 10.2337/cd19-0061 10.1007/s40262-021-01084-0 10.1111/dme.12303 10.2337/dc16-0691 10.1001/jama.2016.1252 10.2337/dci22-0034 10.1016/S2213-8587(13)70144-X 10.2337/dci18-0033 10.4158/EP15959.OR 10.2337/dc12-1333 10.1111/dom.12472 10.1111/dom.12804 10.1097/MLR.0000000000000565 10.1111/dom.14100 10.1016/S0140-6736(21)01919-X 10.1016/j.diabres.2018.06.016 10.1177/193229681300700617 10.1111/dom.12438 10.2337/dc16-1771 10.1016/j.jdiacomp.2017.11.001 10.1016/S2213-8587(13)70090-1 10.7326/M15-2650 10.1002/dmrr.2983 10.1136/bmj.j1321 10.1016/j.eprac.2020.11.002 10.1016/S2213-8587(17)30085-2 10.1056/NEJMoa0806470 10.2337/dci19-0066 10.1111/j.1463-1326.2008.00934.x 10.1016/j.tem.2019.11.007 10.2337/dc14-0649 10.1089/15209150252924094 10.2337/dc12-1205 10.2337/dc14-0990 10.2337/dc14-1625 10.1016/j.diabres.2008.04.007 10.2337/dci21-0043 10.1001/jama.2017.7117 10.1056/NEJMoa1907863 10.2337/dci18-0019 10.4158/EP09117.ORR 10.1001/jama.2022.0078 10.2147/DMSO.S130834 10.1016/S2213-8587(17)30308-X 10.1111/dom.12417 10.1016/S0140-6736(19)32131-2 10.1016/S0140-6736(10)60406-0 10.2337/dc18-1749 10.1016/S2213-8587(19)30184-6 10.7326/0003-4819-157-5-201209040-00508 10.1016/j.mayocp.2014.12.014 10.2337/diacare.26.3.784 10.2337/diacare.25.4.724 10.1503/cmaj.081041 10.1111/dom.14451 10.1016/j.diabres.2016.10.022 10.1111/j.1464-5491.2007.02407.x 10.2337/dci18-0012 10.1002/cpt.1307 10.1007/s13300-019-0673-8 |
| ContentType | Journal Article |
| Copyright | 2022 by the American Diabetes Association. 2022 by the American Diabetes Association 2022 |
| Copyright_xml | – notice: 2022 by the American Diabetes Association. – notice: 2022 by the American Diabetes Association 2022 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| DOI | 10.2337/dc23-S009 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE CrossRef MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1935-5548 |
| EndPage | S157 |
| ExternalDocumentID | PMC9810476 36507650 10_2337_dc23_S009 |
| Genre | Journal Article Review |
| GroupedDBID | --- -ET ..I .XZ 08P 0R~ 18M 29F 2WC 4.4 53G 5GY 5RE 5RS 5VS 6PF 8R4 8R5 AAFWJ AAIKC AAMNW AAWTL AAYEP AAYXX ABOCM ABPPZ ACGFO ACGOD ADBBV AEGXH AENEX AERZD AFOSN AFRAH AHMBA AIAGR ALIPV ALMA_UNASSIGNED_HOLDINGS BAWUL BENPR BTFSW CITATION CS3 DIK DU5 E3Z EBS EDB EMOBN EX3 F5P GX1 H13 HZ~ IAO IEA IHR INH INR IOF IPO KQ8 L7B M0K M5~ O5R O5S O9- OK1 OVD P2P PCD Q2X RHI SV3 TDI TEORI TR2 TWZ VVN W8F WH7 WOQ WOW YHG YOC ZCG ~KM CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c3569-c3cb78d62ca636717226cfc58123e81e8b13d7f3e6874ad96475ccbd9b90ab0a3 |
| ISSN | 0149-5992 1935-5548 |
| IngestDate | Thu Aug 21 18:38:06 EDT 2025 Fri Jul 11 04:36:54 EDT 2025 Mon Jul 21 05:58:40 EDT 2025 Tue Jul 01 04:12:09 EDT 2025 Thu Apr 24 23:08:57 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | Supplement_1 |
| Language | English |
| License | 2022 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/journals/pages/license. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c3569-c3cb78d62ca636717226cfc58123e81e8b13d7f3e6874ad96475ccbd9b90ab0a3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
| OpenAccessLink | https://diabetesjournals.org/care/article-pdf/46/Supplement_1/S140/693669/dc23s009.pdf |
| PMID | 36507650 |
| PQID | 2753668084 |
| PQPubID | 23479 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_9810476 proquest_miscellaneous_2753668084 pubmed_primary_36507650 crossref_primary_10_2337_dc23_S009 crossref_citationtrail_10_2337_dc23_S009 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2023-01-01 |
| PublicationDateYYYYMMDD | 2023-01-01 |
| PublicationDate_xml | – month: 01 year: 2023 text: 2023-01-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Diabetes care |
| PublicationTitleAlternate | Diabetes Care |
| PublicationYear | 2023 |
| Publisher | American Diabetes Association |
| Publisher_xml | – name: American Diabetes Association |
| References | Patel (2023012002244725700_B75) 2016; 54 Buckingham (2023012002244725700_B18) 2015; 38 Pratley (2023012002244725700_B63) 2019; 394 Terauchi (2023012002244725700_B88) 2016; 18 Wysham (2023012002244725700_B92) 2017; 318 Bell (2023012002244725700_B27) 2015; 38 Kang (2023012002244725700_B74) 2018; 143 Bergenstal (2023012002244725700_B19) 2016; 316 Lingvay (2023012002244725700_B46) 2022; 399 Rosenstock (2023012002244725700_B39) 2018; 41 Maruthur (2023012002244725700_B48) 2016; 164 Ahrén (2023012002244725700_B37) 2016; 39 Heller (2023012002244725700_B99) 2013; 5 Hollander (2023012002244725700_B32) 2003; 26 Gerstein (2023012002244725700_B76) 2021; 385 Riddle (2023012002244725700_B84) 2003; 26 Monami (2023012002244725700_B82) 2008; 81 Yeh (2023012002244725700_B15) 2012; 157 Cowart (2023012002244725700_B94) 2020; 38 Dahl (2023012002244725700_B111) 2022; 327 Porcellati (2023012002244725700_B78) 2015; 38 Lipska (2023012002244725700_B96) 2018; 320 Wang (2023012002244725700_B79) 2010; 33 Giorgino (2023012002244725700_B67) 2015; 38 Yki-Järvinen (2023012002244725700_B86) 2006; 49 2023012002244725700_B73 2023012002244725700_B72 Vijan (2023012002244725700_B61) 2014; 174 Mathieu (2023012002244725700_B36) 2016; 39 Aroda (2023012002244725700_B57) 2019; 7 Whitehouse (2023012002244725700_B30) 2002; 25 Mannucci (2023012002244725700_B98) 2009; 11 Cleary (2023012002244725700_B1) 2006; 55 Henry (2023012002244725700_B52) 2012; 66 Lingvay (2023012002244725700_B110) 2016; 315 Maiorino (2023012002244725700_B108) 2017; 40 Tsapas (2023012002244725700_B62) 2020; 173 Pickup (2023012002244725700_B16) 2013; 7 Davies (2023012002244725700_B43) 2018; 41 Singh (2023012002244725700_B64) 2017; 19 Davies (2023012002244725700_B69) 2013; 36 Tauschmann (2023012002244725700_B21) 2018; 392 Babu (2023012002244725700_B53) 2009; 15 Hoogwerf (2023012002244725700_B104) 2021; 27 Ratner (2023012002244725700_B31) 2002; 4 Hermansen (2023012002244725700_B85) 2006; 29 Riddle (2023012002244725700_B101) 2015; 17 Aroda (2023012002244725700_B109) 2016; 39 Marso (2023012002244725700_B90) 2017; 377 Bell (2023012002244725700_B25) 2014; 2 Owens (2023012002244725700_B83) 2017; 124 Rodbard (2023012002244725700_B91) 2013; 30 Tsapas (2023012002244725700_B114) 2021; 23 Blevins (2023012002244725700_B12) 2020; 43 Yki-Järvinen (2023012002244725700_B89) 2015; 17 Zinman (2023012002244725700_B93) 2012; 35 Peters (2023012002244725700_B23) 2013 Levin (2023012002244725700_B65) 2017; 10 Bode (2023012002244725700_B9) 2015; 38 Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group (2023012002244725700_B3) 2016; 39 Matthews (2023012002244725700_B58) 2019; 394 Diamant (2023012002244725700_B106) 2014; 37 Bergenstal (2023012002244725700_B29) 2015; 90 Bergenstal (2023012002244725700_B17) 2013; 369 Frid (2023012002244725700_B28) 2016; 91 Holman (2023012002244725700_B47) 2008; 359 McCall (2023012002244725700_B97) 2012; 41 Eng (2023012002244725700_B107) 2014; 384 Davies (2023012002244725700_B45) 2022; 45 Snaith (2023012002244725700_B40) 2020; 31 Bolli (2023012002244725700_B87) 2015; 17 Danne (2023012002244725700_B41) 2019; 42 Rodbard (2023012002244725700_B113) 2014; 2 Diamant (2023012002244725700_B70) 2010; 375 Abdul-Ghani (2023012002244725700_B55) 2015; 17 Buse (2023012002244725700_B44) 2020; 43 Singh (2023012002244725700_B80) 2009; 180 Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2023012002244725700_B4) 2002; 287 Maloney (2023012002244725700_B60) 2019; 105 Yki-Järvinen (2023012002244725700_B102) 2014; 37 DeWitt (2023012002244725700_B8) 2003; 289 Klaff (2023012002244725700_B11) 2020; 22 Home (2023012002244725700_B14) 2015; 38 Dandona (2023012002244725700_B38) 2017; 5 Taybani (2023012002244725700_B112) 2019; 10 Riddle (2023012002244725700_B71) 2018; 41 Blonde (2023012002244725700_B77) 2009; 11 Lane (2023012002244725700_B13) 2017; 318 Meng (2023012002244725700_B34) 2018; 34 Grant (2023012002244725700_B105) 2022; 61 Garg (2023012002244725700_B20) 2017; 19 Vaz (2023012002244725700_B26) 2018; 62 Petrie (2023012002244725700_B35) 2017; 5 Aroda (2023012002244725700_B51) 2016; 101 Russell-Jones (2023012002244725700_B10) 2017; 40 Bartley (2023012002244725700_B7) 2008; 25 Akturk (2023012002244725700_B103) 2018; 20 Bennett (2023012002244725700_B59) 2011; 154 Aroda (2023012002244725700_B68) 2017; 5 Tricco (2023012002244725700_B6) 2014; 349 Wysham (2023012002244725700_B100) 2016; 22 Abd El Aziz (2023012002244725700_B66) 2017; 19 Holt (2023012002244725700_B5) 2021; 44 Horvath (2023012002244725700_B81) 2007; 2 Cefalu (2023012002244725700_B95) 2018; 41 Phung (2023012002244725700_B56) 2014; 16 Ratner (2023012002244725700_B33) 2004; 21 Nathan (2023012002244725700_B2) 2005; 353 2023012002244725700_B49 Chiang (2023012002244725700_B24) 2014; 37 Cahn (2023012002244725700_B54) 2016; 39 Brown (2023012002244725700_B22) 2019; 381 Out (2023012002244725700_B50) 2018; 32 2023012002244725700_B42 |
| References_xml | – volume: 37 start-page: 2034 year: 2014 ident: 2023012002244725700_B24 article-title: Type 1 diabetes through the life span: a position statement of the American Diabetes Association publication-title: Diabetes Care doi: 10.2337/dc14-1140 – volume: 289 start-page: 2254 year: 2003 ident: 2023012002244725700_B8 article-title: Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review publication-title: JAMA doi: 10.1001/jama.289.17.2254 – volume: 91 start-page: 1231 year: 2016 ident: 2023012002244725700_B28 article-title: New insulin delivery recommendations publication-title: Mayo Clin Proc doi: 10.1016/j.mayocp.2016.06.010 – volume: 41 start-page: 57 year: 2012 ident: 2023012002244725700_B97 article-title: Insulin therapy and hypoglycemia publication-title: Endocrinol Metab Clin North Am doi: 10.1016/j.ecl.2012.03.001 – volume: 29 start-page: 1269 year: 2006 ident: 2023012002244725700_B85 article-title: A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes publication-title: Diabetes Care doi: 10.2337/dc05-1365 – volume: 39 start-page: 1693 year: 2016 ident: 2023012002244725700_B37 article-title: Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: the ADJUNCT TWO randomized trial publication-title: Diabetes Care doi: 10.2337/dc16-0690 – ident: 2023012002244725700_B72 – volume: 320 start-page: 53 year: 2018 ident: 2023012002244725700_B96 article-title: Association of initiation of basal insulin analogs vs neutral protamine hagedorn insulin with hypoglycemia-related emergency department visits or hospital admissions and with glycemic control in patients with type 2 diabetes publication-title: JAMA doi: 10.1001/jama.2018.7993 – volume: 392 start-page: 1321 year: 2018 ident: 2023012002244725700_B21 article-title: Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial publication-title: Lancet doi: 10.1016/S0140-6736(18)31947-0 – volume: 316 start-page: 1407 year: 2016 ident: 2023012002244725700_B19 article-title: Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes publication-title: JAMA doi: 10.1001/jama.2016.11708 – volume: 19 start-page: 155 year: 2017 ident: 2023012002244725700_B20 article-title: Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes publication-title: Diabetes Technol Ther doi: 10.1089/dia.2016.0421 – volume: 49 start-page: 442 year: 2006 ident: 2023012002244725700_B86 article-title: Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study publication-title: Diabetologia doi: 10.1007/s00125-005-0132-0 – volume: 33 start-page: 1555 year: 2010 ident: 2023012002244725700_B79 article-title: Dose-response effects of insulin glargine in type 2 diabetes publication-title: Diabetes Care doi: 10.2337/dc09-2011 – volume: 38 start-page: 1008 year: 2015 ident: 2023012002244725700_B27 article-title: Impact of fat, protein, and glycemic index on postprandial glucose control in type 1 diabetes: implications for intensive diabetes management in the continuous glucose monitoring era publication-title: Diabetes Care doi: 10.2337/dc15-0100 – volume: 55 start-page: 3556 year: 2006 ident: 2023012002244725700_B1 article-title: The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study publication-title: Diabetes doi: 10.2337/db06-0653 – volume: 39 start-page: 1378 year: 2016 ident: 2023012002244725700_B3 article-title: Mortality in type 1 diabetes in the DCCT/EDIC versus the general population publication-title: Diabetes Care doi: 10.2337/dc15-2399 – volume: 39 start-page: S137 year: 2016 ident: 2023012002244725700_B54 article-title: Clinical considerations for use of initial combination therapy in type 2 diabetes publication-title: Diabetes Care doi: 10.2337/dcS15-3007 – volume: 16 start-page: 410 year: 2014 ident: 2023012002244725700_B56 article-title: Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis publication-title: Diabetes Obes Metab doi: 10.1111/dom.12233 – volume: 369 start-page: 224 year: 2013 ident: 2023012002244725700_B17 article-title: Threshold-based insulin-pump interruption for reduction of hypoglycemia publication-title: N Engl J Med doi: 10.1056/NEJMoa1303576 – volume: 26 start-page: 3080 year: 2003 ident: 2023012002244725700_B84 article-title: The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients publication-title: Diabetes Care doi: 10.2337/diacare.26.11.3080 – volume: 40 start-page: 614 year: 2017 ident: 2023012002244725700_B108 article-title: Insulin and glucagon-like peptide 1 receptor agonist combination therapy in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials publication-title: Diabetes Care doi: 10.2337/dc16-1957 – volume: 38 start-page: 1197 year: 2015 ident: 2023012002244725700_B18 article-title: Predictive low-glucose insulin suspension reduces duration of nocturnal hypoglycemia in children without increasing ketosis publication-title: Diabetes Care doi: 10.2337/dc14-3053 – volume: 38 start-page: 2266 year: 2015 ident: 2023012002244725700_B9 article-title: Inhaled technosphere insulin compared with injected prandial insulin in type 1 diabetes: a randomized 24-week trial publication-title: Diabetes Care doi: 10.2337/dc15-0075 – volume: 66 start-page: 446 year: 2012 ident: 2023012002244725700_B52 article-title: Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial publication-title: Int J Clin Pract doi: 10.1111/j.1742-1241.2012.02911.x – volume: 11 start-page: 623 year: 2009 ident: 2023012002244725700_B77 article-title: Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets–the TITRATE study publication-title: Diabetes Obes Metab doi: 10.1111/j.1463-1326.2009.01060.x – volume: 19 start-page: 228 year: 2017 ident: 2023012002244725700_B64 article-title: Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis publication-title: Diabetes Obes Metab doi: 10.1111/dom.12805 – volume: 42 start-page: 1147 year: 2019 ident: 2023012002244725700_B41 article-title: International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors publication-title: Diabetes Care doi: 10.2337/dc18-2316 – volume: 353 start-page: 2643 year: 2005 ident: 2023012002244725700_B2 article-title: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes publication-title: N Engl J Med doi: 10.1056/NEJMoa052187 – volume: 174 start-page: 1227 year: 2014 ident: 2023012002244725700_B61 article-title: Effect of patients’ risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus publication-title: JAMA Intern Med doi: 10.1001/jamainternmed.2014.2894 – ident: 2023012002244725700_B49 – volume: 384 start-page: 2228 year: 2014 ident: 2023012002244725700_B107 article-title: Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis publication-title: Lancet doi: 10.1016/S0140-6736(14)61335-0 – volume: 17 start-page: 1142 year: 2015 ident: 2023012002244725700_B89 article-title: Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension publication-title: Diabetes Obes Metab doi: 10.1111/dom.12532 – volume: 154 start-page: 602 year: 2011 ident: 2023012002244725700_B59 article-title: Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations publication-title: Ann Intern Med doi: 10.7326/0003-4819-154-9-201105030-00336 – volume: 385 start-page: 896 year: 2021 ident: 2023012002244725700_B76 article-title: Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes publication-title: N Engl J Med doi: 10.1056/NEJMoa2108269 – volume: 173 start-page: 278 year: 2020 ident: 2023012002244725700_B62 article-title: Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis publication-title: Ann Intern Med doi: 10.7326/M20-0864 – volume: 39 start-page: 1972 year: 2016 ident: 2023012002244725700_B109 article-title: Efficacy and safety of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin: the LixiLan-L randomized trial publication-title: Diabetes Care doi: 10.2337/dc16-1495 – volume: 101 start-page: 1754 year: 2016 ident: 2023012002244725700_B51 article-title: Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2015-3754 – volume: 18 start-page: 366 year: 2016 ident: 2023012002244725700_B88 article-title: New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2) publication-title: Diabetes Obes Metab doi: 10.1111/dom.12618 – volume: 377 start-page: 723 year: 2017 ident: 2023012002244725700_B90 article-title: Efficacy and safety of degludec versus glargine in type 2 diabetes publication-title: N Engl J Med doi: 10.1056/NEJMoa1615692 – volume: 287 start-page: 2563 year: 2002 ident: 2023012002244725700_B4 article-title: Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus publication-title: JAMA doi: 10.1001/jama.287.19.2563 – volume: 62 start-page: 337 year: 2018 ident: 2023012002244725700_B26 article-title: Effectiveness and safety of carbohydrate counting in the management of adult patients with type 1 diabetes mellitus: a systematic review and meta-analysis publication-title: Arch Endocrinol Metab – volume: 37 start-page: 2763 year: 2014 ident: 2023012002244725700_B106 article-title: Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes publication-title: Diabetes Care doi: 10.2337/dc14-0876 – volume: 349 start-page: g5459 year: 2014 ident: 2023012002244725700_B6 article-title: Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis publication-title: BMJ doi: 10.1136/bmj.g5459 – volume: 38 start-page: 2217 year: 2015 ident: 2023012002244725700_B14 article-title: New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 1 diabetes: a randomized, phase 3a, open-label clinical trial (EDITION 4) publication-title: Diabetes Care doi: 10.2337/dc15-0249 – volume: 21 start-page: 1204 year: 2004 ident: 2023012002244725700_B33 article-title: Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: a 1-year, randomized controlled trial publication-title: Diabet Med doi: 10.1111/j.1464-5491.2004.01319.x – volume: 5 start-page: 482 year: 2013 ident: 2023012002244725700_B99 article-title: Meta-analysis of insulin aspart versus regular human insulin used in a basal-bolus regimen for the treatment of diabetes mellitus publication-title: J Diabetes doi: 10.1111/1753-0407.12060 – volume: 20 start-page: 639 year: 2018 ident: 2023012002244725700_B103 article-title: Improved postprandial glucose with inhaled technosphere insulin compared with insulin aspart in patients with type 1 diabetes on multiple daily injections: the STAT study publication-title: Diabetes Technol Ther doi: 10.1089/dia.2018.0200 – volume: 394 start-page: 39 year: 2019 ident: 2023012002244725700_B63 article-title: Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial publication-title: Lancet doi: 10.1016/S0140-6736(19)31271-1 – volume: 5 start-page: 597 year: 2017 ident: 2023012002244725700_B35 article-title: Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial publication-title: Lancet Diabetes Endocrinol doi: 10.1016/S2213-8587(17)30194-8 – volume: 43 start-page: 2991 year: 2020 ident: 2023012002244725700_B12 article-title: Randomized double-blind clinical trial comparing ultra rapid lispro with lispro in a basal-bolus regimen in patients with type 2 diabetes: PRONTO-T2D publication-title: Diabetes Care doi: 10.2337/dc19-2550 – volume: 318 start-page: 33 year: 2017 ident: 2023012002244725700_B13 article-title: Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 1 diabetes: the SWITCH 1 randomized clinical trial publication-title: JAMA doi: 10.1001/jama.2017.7115 – volume: 38 start-page: 304 year: 2020 ident: 2023012002244725700_B94 article-title: Overbasalization: addressing hesitancy in treatment intensification beyond basal insulin publication-title: Clin Diabetes doi: 10.2337/cd19-0061 – volume: 61 start-page: 413 year: 2022 ident: 2023012002244725700_B105 article-title: Comparison of pharmacokinetics and pharmacodynamics of inhaled technosphere insulin and subcutaneous insulin lispro in the treatment of type 1 diabetes mellitus publication-title: Clin Pharmacokinet doi: 10.1007/s40262-021-01084-0 – volume: 30 start-page: 1298 year: 2013 ident: 2023012002244725700_B91 article-title: Comparison of insulin degludec with insulin glargine in insulin-naive subjects with type 2 diabetes: a 2-year randomized, treat-to-target trial publication-title: Diabet Med doi: 10.1111/dme.12303 – volume: 39 start-page: 1702 year: 2016 ident: 2023012002244725700_B36 article-title: Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE treat-to-target randomized trial publication-title: Diabetes Care doi: 10.2337/dc16-0691 – volume: 315 start-page: 898 year: 2016 ident: 2023012002244725700_B110 article-title: Effect of insulin glargine up-titration vs insulin degludec/liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes: the DUAL V randomized clinical trial publication-title: JAMA doi: 10.1001/jama.2016.1252 – volume: 45 start-page: 2753 year: 2022 ident: 2023012002244725700_B45 article-title: Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) publication-title: Diabetes Care doi: 10.2337/dci22-0034 – volume: 2 start-page: 133 year: 2014 ident: 2023012002244725700_B25 article-title: Efficacy of carbohydrate counting in type 1 diabetes: a systematic review and meta-analysis publication-title: Lancet Diabetes Endocrinol doi: 10.1016/S2213-8587(13)70144-X – volume: 41 start-page: 2669 year: 2018 ident: 2023012002244725700_B43 article-title: Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) publication-title: Diabetes Care doi: 10.2337/dci18-0033 – volume: 22 start-page: 653 year: 2016 ident: 2023012002244725700_B100 article-title: Effect of total daily dose on efficacy, dosing, and safety of 2 dose titration regimens of human regular U500 insulin in severely insulin-resistant patients with type 2 diabetes publication-title: Endocr Pract doi: 10.4158/EP15959.OR – volume: 36 start-page: 1368 year: 2013 ident: 2023012002244725700_B69 article-title: Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas publication-title: Diabetes Care doi: 10.2337/dc12-1333 – volume: 17 start-page: 835 year: 2015 ident: 2023012002244725700_B101 article-title: One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension publication-title: Diabetes Obes Metab doi: 10.1111/dom.12472 – volume: 19 start-page: 216 year: 2017 ident: 2023012002244725700_B66 article-title: A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients publication-title: Diabetes Obes Metab doi: 10.1111/dom.12804 – volume: 54 start-page: 796 year: 2016 ident: 2023012002244725700_B75 article-title: Social determinants of health, cost-related nonadherence, and cost-reducing behaviors among adults with diabetes: findings from the National Health interview survey publication-title: Med Care doi: 10.1097/MLR.0000000000000565 – volume: 22 start-page: 1799 year: 2020 ident: 2023012002244725700_B11 article-title: Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: Results from the 26-week PRONTO-T1D study publication-title: Diabetes Obes Metab doi: 10.1111/dom.14100 – volume: 399 start-page: 394 year: 2022 ident: 2023012002244725700_B46 article-title: Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation publication-title: Lancet doi: 10.1016/S0140-6736(21)01919-X – volume: 143 start-page: 24 year: 2018 ident: 2023012002244725700_B74 article-title: Cost-related medication non-adherence among U.S. adults with diabetes publication-title: Diabetes Res Clin Pract doi: 10.1016/j.diabres.2018.06.016 – volume: 7 start-page: 1567 year: 2013 ident: 2023012002244725700_B16 article-title: The evidence base for diabetes technology: appropriate and inappropriate meta-analysis publication-title: J Diabetes Sci Technol doi: 10.1177/193229681300700617 – volume: 17 start-page: 386 year: 2015 ident: 2023012002244725700_B87 article-title: New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3) publication-title: Diabetes Obes Metab doi: 10.1111/dom.12438 – volume: 40 start-page: 943 year: 2017 ident: 2023012002244725700_B10 article-title: Fast-acting insulin aspart improves glycemic control in basal-bolus treatment for type 1 diabetes: results of a 26-week multicenter, active-controlled, treat-to-target, randomized, parallel-group trial (onset 1) publication-title: Diabetes Care doi: 10.2337/dc16-1771 – volume: 32 start-page: 171 year: 2018 ident: 2023012002244725700_B50 article-title: Long-term treatment with metformin in type 2 diabetes and methylmalonic acid: post hoc analysis of a randomized controlled 4.3-year trial publication-title: J Diabetes Complications doi: 10.1016/j.jdiacomp.2017.11.001 – volume: 2 start-page: 30 year: 2014 ident: 2023012002244725700_B113 article-title: Treatment intensification with stepwise addition of prandial insulin aspart boluses compared with full basal-bolus therapy (FullSTEP Study): a randomised, treat-to-target clinical trial publication-title: Lancet Diabetes Endocrinol doi: 10.1016/S2213-8587(13)70090-1 – volume: 164 start-page: 740 year: 2016 ident: 2023012002244725700_B48 article-title: Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis publication-title: Ann Intern Med doi: 10.7326/M15-2650 – volume: 34 start-page: e2983 year: 2018 ident: 2023012002244725700_B34 article-title: Effect of metformin on glycaemic control in patients with type 1 diabetes: a meta-analysis of randomized controlled trials publication-title: Diabetes Metab Res Rev doi: 10.1002/dmrr.2983 – ident: 2023012002244725700_B42 doi: 10.1136/bmj.j1321 – volume: 27 start-page: 38 year: 2021 ident: 2023012002244725700_B104 article-title: Results of a 24-week trial of technosphere insulin versus insulin aspart in type 2 diabetes publication-title: Endocr Pract doi: 10.1016/j.eprac.2020.11.002 – volume: 5 start-page: 355 year: 2017 ident: 2023012002244725700_B68 article-title: Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial publication-title: Lancet Diabetes Endocrinol doi: 10.1016/S2213-8587(17)30085-2 – volume: 359 start-page: 1577 year: 2008 ident: 2023012002244725700_B47 article-title: 10-year follow-up of intensive glucose control in type 2 diabetes publication-title: N Engl J Med doi: 10.1056/NEJMoa0806470 – volume: 43 start-page: 487 year: 2020 ident: 2023012002244725700_B44 article-title: 2019 Update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) publication-title: Diabetes Care doi: 10.2337/dci19-0066 – volume: 11 start-page: 53 year: 2009 ident: 2023012002244725700_B98 article-title: Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: a meta-analysis publication-title: Diabetes Obes Metab doi: 10.1111/j.1463-1326.2008.00934.x – volume: 31 start-page: 150 year: 2020 ident: 2023012002244725700_B40 article-title: Reducing type 1 diabetes mortality: role for adjunctive therapies? publication-title: Trends Endocrinol Metab doi: 10.1016/j.tem.2019.11.007 – volume: 38 start-page: 503 year: 2015 ident: 2023012002244725700_B78 article-title: Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes publication-title: Diabetes Care doi: 10.2337/dc14-0649 – volume: 4 start-page: 51 year: 2002 ident: 2023012002244725700_B31 article-title: Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes publication-title: Diabetes Technol Ther doi: 10.1089/15209150252924094 – volume: 35 start-page: 2464 year: 2012 ident: 2023012002244725700_B93 article-title: Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long) publication-title: Diabetes Care doi: 10.2337/dc12-1205 – volume: 37 start-page: 3235 year: 2014 ident: 2023012002244725700_B102 article-title: New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2) publication-title: Diabetes Care doi: 10.2337/dc14-0990 – volume: 38 start-page: 2241 year: 2015 ident: 2023012002244725700_B67 article-title: Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2) publication-title: Diabetes Care doi: 10.2337/dc14-1625 – volume: 81 start-page: 184 year: 2008 ident: 2023012002244725700_B82 article-title: Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis publication-title: Diabetes Res Clin Pract doi: 10.1016/j.diabres.2008.04.007 – volume: 2 start-page: CD005613 year: 2007 ident: 2023012002244725700_B81 article-title: Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus publication-title: Cochrane Database Syst Rev – volume: 44 start-page: 2589 year: 2021 ident: 2023012002244725700_B5 article-title: The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) publication-title: Diabetes Care doi: 10.2337/dci21-0043 – volume: 318 start-page: 45 year: 2017 ident: 2023012002244725700_B92 article-title: Effect of insulin degludec vs insulin glargine u100 on hypoglycemia in patients with type 2 diabetes: the SWITCH 2 randomized clinical trial publication-title: JAMA doi: 10.1001/jama.2017.7117 – volume: 381 start-page: 1707 year: 2019 ident: 2023012002244725700_B22 article-title: Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes publication-title: N Engl J Med doi: 10.1056/NEJMoa1907863 – volume: 41 start-page: 1299 year: 2018 ident: 2023012002244725700_B95 article-title: Conclusions and recommendations publication-title: Diabetes Care doi: 10.2337/dci18-0019 – volume-title: American Diabetes Association/JDRF Type 1 Diabetes Sourcebook year: 2013 ident: 2023012002244725700_B23 – volume: 15 start-page: 696 year: 2009 ident: 2023012002244725700_B53 article-title: Safe and simple emergency department discharge therapy for patients with type 2 diabetes mellitus and severe hyperglycemia publication-title: Endocr Pract doi: 10.4158/EP09117.ORR – volume: 327 start-page: 534 year: 2022 ident: 2023012002244725700_B111 article-title: Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial publication-title: JAMA doi: 10.1001/jama.2022.0078 – volume: 10 start-page: 123 year: 2017 ident: 2023012002244725700_B65 article-title: Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research publication-title: Diabetes Metab Syndr Obes doi: 10.2147/DMSO.S130834 – volume: 5 start-page: 864 year: 2017 ident: 2023012002244725700_B38 article-title: Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial publication-title: Lancet Diabetes Endocrinol doi: 10.1016/S2213-8587(17)30308-X – volume: 17 start-page: 268 year: 2015 ident: 2023012002244725700_B55 article-title: Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial publication-title: Diabetes Obes Metab doi: 10.1111/dom.12417 – volume: 394 start-page: 1519 year: 2019 ident: 2023012002244725700_B58 article-title: Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial publication-title: Lancet doi: 10.1016/S0140-6736(19)32131-2 – volume: 375 start-page: 2234 year: 2010 ident: 2023012002244725700_B70 article-title: Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial publication-title: Lancet doi: 10.1016/S0140-6736(10)60406-0 – volume: 41 start-page: 2560 year: 2018 ident: 2023012002244725700_B39 article-title: Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials publication-title: Diabetes Care doi: 10.2337/dc18-1749 – volume: 7 start-page: 596 year: 2019 ident: 2023012002244725700_B57 article-title: Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial publication-title: Lancet Diabetes Endocrinol doi: 10.1016/S2213-8587(19)30184-6 – volume: 157 start-page: 336 year: 2012 ident: 2023012002244725700_B15 article-title: Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis publication-title: Ann Intern Med doi: 10.7326/0003-4819-157-5-201209040-00508 – volume: 90 start-page: 329 year: 2015 ident: 2023012002244725700_B29 article-title: Safety and efficacy of insulin therapy delivered via a 4mm pen needle in obese patients with diabetes publication-title: Mayo Clin Proc doi: 10.1016/j.mayocp.2014.12.014 – volume: 26 start-page: 784 year: 2003 ident: 2023012002244725700_B32 article-title: Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial publication-title: Diabetes Care doi: 10.2337/diacare.26.3.784 – ident: 2023012002244725700_B73 – volume: 25 start-page: 724 year: 2002 ident: 2023012002244725700_B30 article-title: A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes publication-title: Diabetes Care doi: 10.2337/diacare.25.4.724 – volume: 180 start-page: 385 year: 2009 ident: 2023012002244725700_B80 article-title: Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis publication-title: CMAJ doi: 10.1503/cmaj.081041 – volume: 23 start-page: 2116 year: 2021 ident: 2023012002244725700_B114 article-title: Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis publication-title: Diabetes Obes Metab doi: 10.1111/dom.14451 – volume: 124 start-page: 57 year: 2017 ident: 2023012002244725700_B83 article-title: Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy publication-title: Diabetes Res Clin Pract doi: 10.1016/j.diabres.2016.10.022 – volume: 25 start-page: 442 year: 2008 ident: 2023012002244725700_B7 article-title: Long-term efficacy and safety of insulin detemir compared to neutral protamine Hagedorn insulin in patients with type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial publication-title: Diabet Med doi: 10.1111/j.1464-5491.2007.02407.x – volume: 41 start-page: 929 year: 2018 ident: 2023012002244725700_B71 article-title: The cost of diabetes care-an elephant in the room publication-title: Diabetes Care doi: 10.2337/dci18-0012 – volume: 105 start-page: 1213 year: 2019 ident: 2023012002244725700_B60 article-title: A model-based meta-analysis of 24 antihyperglycemic drugs for type 2 diabetes: comparison of treatment effects at therapeutic doses publication-title: Clin Pharmacol Ther doi: 10.1002/cpt.1307 – volume: 10 start-page: 1869 year: 2019 ident: 2023012002244725700_B112 article-title: Simplifying complex insulin regimens while preserving good glycemic control in type 2 diabetes publication-title: Diabetes Ther doi: 10.1007/s13300-019-0673-8 |
| SSID | ssj0004488 |
| Score | 2.7433212 |
| SecondaryResourceType | review_article |
| Snippet | The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide... The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide... |
| SourceID | pubmedcentral proquest pubmed crossref |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | S140 |
| SubjectTerms | Diabetes Mellitus - drug therapy Endocrinology Humans Reference Standards Societies, Medical Standard of Care Standards of Care |
| Title | 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023 |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/36507650 https://www.proquest.com/docview/2753668084 https://pubmed.ncbi.nlm.nih.gov/PMC9810476 |
| Volume | 46 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bi9QwFA66wrIv4t3xRhQfhKVj07Rp6tsi6qLsosyM7FvJrezA2A47HWH313uS9DquoL6Eock0kO8jc86Zc76D0Gsw6QnPTBYUKadBrHgYiIKYgElNJPyiJ6HrRXByyo4X8eez5KxP5XXVJbWcqqtr60r-B1V4BrjaKtl_QLZ7KTyAz4AvjIAwjH-FcTY9_NpLTy-VtSldhZTXbfi0ulQu933eZpNb_3_WBA82vjTrwqmGNIkxm8D2OR8arO2Ek7DuEz1m4tJHSU-356KPhx6tzHpd-doXcbUUPZ0q7azU71ZtQwyyFF2l8tYBLX6CT62tgHQz3wQjIjoIRhh_gWY0CcBE4cMbtgkyeia5bqWHZHBpzohXbNq9zSPq9AC0gn1moVNRqAeorn84WCnYmCnz6rU70tnt1E10KwIvwja4-PJtICYPl5cXm7I7ve32OUD77TfH1spvLshuJu3ANJnfQbcbnwIfeYLcRTdMeQ_tnzRZE_fRIpviEU9wzxNcV7jlCe548g53LMFVgS1L8LLEI5Y8QIuPH-bvj4OmnUagaMIyGJVMuWaREowycOPB8laFSsDEo4YTwyWhOi2oYTyNhbYlyolSUmcyC4UMBX2I9sqqNI8RBp-dSq2Z0JGOIyJ5UVAlJOURKUSR0gl60x5brhqtedvyZJWDz2kPO7eHndvDnqBX3dK1F1i5btHL9uxzuP7sf1qiNNV2k0fgbjPbPiaeoEcei-41LYgTlI5Q6hZYafXxTLk8dxLrGbcSJuzJH9_5FB30_H-G9uqLrXkO5mktXziS_QJpCI8O |
| linkProvider | Colorado Alliance of Research Libraries |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=9.+Pharmacologic+Approaches+to+Glycemic+Treatment%3A+Standards+of+Care+in+Diabetes-2023&rft.jtitle=Diabetes+care&rft.au=ElSayed%2C+Nuha+A&rft.au=Aleppo%2C+Grazia&rft.au=Aroda%2C+Vanita+R&rft.au=Bannuru%2C+Raveendhara+R&rft.date=2023-01-01&rft.eissn=1935-5548&rft.volume=46&rft.issue=Suppl+1&rft.spage=S140&rft_id=info:doi/10.2337%2Fdc23-S009&rft_id=info%3Apmid%2F36507650&rft.externalDocID=36507650 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0149-5992&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0149-5992&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0149-5992&client=summon |